AzTrials
AzTrials

Acute Decompensated Heart FailureNCT02289508

Role of USCOM in Adult Patients With Heart Failure

An observational study of Acute Decompensated Heart Failure and Congestive Heart Failure Compensated, run by Chinese University of Hong Kong at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Objective: The Ultrasonic Cardiac Output Monitor (USCOM) is a non-invasive, quantitative method for measuring and monitoring cardiovascular haemodynamic parameters in patients. The aims of this study are: 1. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Ultrasonic cardiac output monitor and Echocardiography
Type of treatment
Medical device
How many people
242 participants
Where
1 siteChina
Study dates
Nov 2014to 6 Feb 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients will be screened and recruited from adult patients either scheduled for elective 2D-echo at a cardiology clinic at the Prince of Wales Hospital, or attending the emergency department at the Prince of Wales Hospital.

Who may be able to join

  • Age ≥ 18 years, AND
  • Written informed consent by patient or nearest relative where appropriate, AND Either
  • Referred for echocardiography, OR
  • At least one typical symptom and one typical sign consistent with possible heart failure, OR
  • Healthy volunteers

Who cannot join

  • Age <18 years
  • Prior enrollment in study
  • Patients with known or suspected pregnancy

Trial locations and contacts

1 site in 1 country.

China1 site
  • Prince of Wales Hospital

    Hong Kong

Other trials in China

About this study

Official title: Diagnostic and Prognostic Role of USCOM in Adult Patients With Heart Failure-A Prospective Observational Study

Objective:

The Ultrasonic Cardiac Output Monitor (USCOM) is a non-invasive, quantitative method for measuring and monitoring cardiovascular haemodynamic parameters in patients. The aims of this study are:

Read more
  1. To investigate whether USCOM-derived haemodynamic parameters such as Cardiac output (CO), inotropy and oxygen delivery (DO2) have a role in the diagnosis of patients with a compensated heart failure syndrome (cHFS) or acute decompensated heart failure syndrome (adHFS)
  2. To investigate whether USCOM-derived haemodynamic parameters such as CO, inotropy and DO2 correlate with heart failure staging, especially New York Heart Association (NYHA) class and American Heart Association (AHA) stage.
  3. To investigate whether USCOM-derived haemodynamic parameters such as velocity time interval (vti), stroke volume (SV), CO, SV index (SVI), CO index (CI), inotropy and DO2 correlate with ejection fraction.
  4. To investigate whether USCOM-derived haemodynamic variables may be used as prognostic indicators of 30-day, 6-month and 1-year Major Adverse Cardiac Events (MACE).
  5. To evaluate the agreement between hemodynamic measurements obtained using the Ultrasonic Cardiac Output Monitor (USCOM®; USCOM Ltd., Sydney, Australia), and reference standards as determined by 2 Dimensional echocardiography (2D-echo) measurements in groups of haemodynamically stable and unstable adult patients.

Design:

This prospective observational cohort study will be conducted in the Prince of Wales Hospital in Hong Kong.

Setting and Subjects:

Patients will be screened and recruited from adult patients either scheduled for elective 2D-echo at a cardiology clinic at the Prince of Wales Hospital, or attending the emergency department at the Prince of Wales Hospital.

Interventions:

Haemodynamic measurements made using the USCOM and 2D-echo will be compared. In order to assess inter-observer variability, a second, blinded operator will repeated 15% of scans.

Read the detailed description

Acute heart failure syndromes (aHFS) cause almost 1 million hospitalizations annually in the United States and are the leading cause of hospitalization in persons aged over 65 years. In 2003, inpatient management of aHFS cost an estimated $12.7 billion in the United States. In 2003, 12.5% of the population in Hong Kong were aged over 65, the third highest proportion of elderly among all countries, and it is postulated that by 2033, the proportion of the elderly in the population will increase to 25%. With the growing elderly population, and the increasing prevalence of hypertension and ischemic heart disease (the major causes of heart failure), heart failure has become a major health care issue globally. In western countries the incidence ranges from 1 to 10 cases/1000/year. Other studies suggest that heart failure is a large and growing public health burden throughout Europe.

Acute exacerbation of heart failure symptoms is a common emergency department (ED) presentation and is known as acute decompensated heart failure (adHF). Acute decompensated heart failure represents the single greatest cost to the US hospitals funded by Medicaid. In Hong Kong (HK), the incidence rate of heart failure was 3-3.8/1000/year rising to 20/1000/year in women over the age of 85 years in recent years. It has been estimated that 7% of all acute medical admissions was due to this condition. In recent years there has been a 10% annual increase in admissions for patients with adHF. Currently in Hong Kong, the vast majority of ED patients with adHF are admitted as inpatients to hospital. In 2005, an audit of outcomes in patients with acute cardiogenic pulmonary oedema, the most severe manifestation of heart failure, presenting to the emergency department at the Prince of Wales Hospital showed that nearly 30% of patients die within 30 days, and a further 30% require readmission within 30 days. Recent evidence from the USA suggests that ED operated observation units are effective in managing low to medium risk adHF patients, reducing length of stay (LOS) for these patients without adversely affecting readmission rate, morbidity and mortality.

2 Dimensional echocardiography (2D-echo) is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. In stable settings, heart failure is often characterized and classified according to ejection fraction measured by echocardiography which may be considered a pragmatic gold standard. However, the use of 2D-echo requires highly trained personnel. Obtaining measurements and calculating fundamental cardiovascular parameters such as cardiac output (CO)may take anywhere between 30 to 45 minutes, which is impractical for any setting, let alone an acute care setting. Further, such personnel are frequently not available in emergency departments. The feasibility of real time haemodynamic assessments is therefore limited with 2D-echo. More sophisticated echocardiographic techniques have been developed in an attempt to overcome the problems of sensitivity to preload and particularly afterload, but have achieved little penetration in critical care.

In acute critical care settings, the diagnosis of adHF is based on the history and clinical signs, sometimes aided by echocardiography, chest radiography and blood markers such as B-type Natriuretic Peptide (BNP). The value of BNP over clinical assessment in patients presenting with dyspnoea has been questioned and there is a need for other tools to improve diagnosis. Commencement, dosing, and withdrawal of vasopressors, vasodilators, and inotropes is still largely based on clinical assessment, sometimes assisted by measurement of surrogates of inotropy such as ejection fraction (EF) or aortic ejection velocity, despite the well-known shortcomings of these indices in critical care. This is particularly so in complex surgical patients where vascular tone and fluid loading status are highly variable and changing.

Heart failure is an abnormality of cardiac structure or function leading to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures (or only at the expense of increased filling pressures). The commonest causes are hypertension or ischemic heart disease. If this definition holds, then heart failure should be associated with some measure of reduction in inotropy or oxygen delivery. Until recently there was no simple non-invasive, bedside test that could aid the assessment of patients with heart failure. Whilst inotropy (or myocardial contractility) as a concept is well known to all clinicians, it is seldom thought of as a measurable quantity.

USCOM has been introduced as a non-invasive bedside haemodynamic monitoring tool that utilizes continuous-wave Doppler ultrasound. The USCOM has a number of advantages. It accuracy, validity and reasonable precision has been confirmed by many studies and in a variety of contexts. It is easily portable, takes only several minutes to obtain reliable measurements in most cases, and can be conducted by trained physicians or nurses.

Some studies have shown good agreement between USCOM and echocardiography but others have been less convincing. With this in mind, there is still a need for further studies to confirm or refute levels of agreement between USCOM and echocardiography.

The potential utility of USCOM for assessing patients with adHF has recently been suggested. Inotropy measurements derived from USCOM are greatly reduced in patients with New York Heart Association (NYHA) Class IV and American Heart association (AHA) stage C, acute left ventricular failure, when compared with healthy controls. These findings have led to the proposal that as USCOM can measure inotropy, then it could be used to assess and to manage heart failure. Although inotropy, derived by USCOM, is low in patients with adHF and NYHA class IV, nevertheless there is no evidence of a dose-relationship between USCOM-derived inotropy and NYHA class, or of a correlation with increasing severity of adHF, with ejection fraction.

Many, if not most, emergency departments throughout the world do not have 2D-echo available 24 hours a day, if at all. The value of BNP testing to improve outcomes has been questioned but even if used, it is frequently not available in many hospitals. As such the assessment and diagnosis of heart failure, and the means to monitor the effect of therapy, constitutes a major unmet need in clinical practice and especially in emergency departments.

Aim

The overall aim of this study is to investigate whether USCOM-derived haemodynamic parameters may have diagnostic, risk-stratification, prognostic and therapeutic monitoring potential in patients with suspected heart failure. The specific objectives are:

  1. To investigate whether USCOM-derived haemodynamic parameters such as CO, inotropy and oxygen delivery (DO2) have a role in the diagnosis of patients with a compensated heart failure syndrome (cHFS) or acute decompensated heart failure syndrome (adHFS)
  2. To investigate whether USCOM-derived haemodynamic parameters such as CO, inotropy and DO2 correlate with heart failure staging, especially NYHA class and AHA stage.
  3. To investigate whether USCOM-derived haemodynamic parameters such as velocity time interval (vti), stroke volume (SV), CO, SV index (SVI), CO index (CI), inotropy and DO2 correlate with ejection fraction.
  4. To investigate whether USCOM-derived haemodynamic variables may be used as prognostic indicators of 30-day, 6-month and 1-year Major Adverse Cardiac Events (MACE).
  5. To evaluate the agreement between hemodynamic measurements obtained using the Ultrasonic Cardiac Output Monitor (USCOM®; USCOM Ltd., Sydney, Australia), and reference standards as determined by 2D-echo measurements in groups of haemodynamically stable and unstable adult patients.

Data collection and measurable parameters

  • Demographics including sex, age, height and weight
  • Chief complaints, concurrent illnesses and significant past history
  • Clinical signs including respiration rate, heart rate, systolic blood pressure, diastolic blood pressure, oxygen saturation and CGS.
  • USCOM derived haemodynamic parameters
  • Full blood examination, urea and electrolytes, arterial or venous blood gases, blood glucose, lactate, BNP, ECG and chest x-ray
  • ED diagnosis, disposition from ED, hospital length of stay, ICU length of stay, hospital diagnosis and in-hospital mortality All the above data will be entered into a database that is securely stored with access only by the investigators.

Definition of haemodynamic parameters:

  • Flow time corrected (FTc) is calculated using Bazett's formula: FTc = FT/√tHR, where tHR = the heart beat period in seconds (s). The unit of FTc is ms.
  • Velocity time integral (vti) is the integral of the flow profile, i.e. the distance the blood travels in one beat. The unit of vti is m/s.
  • Cardiac output (CO) is the volume of blood pumped by the heart in one minute: CO = SV x HR. The unit is l/min.
  • Cardiac index (CI) is equal to CO divided by BSA. The unit is l/min/m2.
  • Inotropy index refers to (Potential energy + Kinetic energy) divided by body surface area. The unit of inotropy is W/m2.
  • Minute distance (MD) is the distance a blood cell travels in metres per minute (m/min). MD = HR x vti, where vti = velocity time integral or stroke distance, which is the distance in centimetres (cm) a single reflector travels per cycle, and is defined as the area of the flow.
  • Stroke volume (SV) is the volume of blood ejected from the heart during one systolic stroke. SV = vti x πr2,where πr2 = flow cross sectional area. The unit of SV is ml.
  • Stroke volume index (SVI) is SV divided by BSA and the unit is ml/m2.
  • Stroke volume variation (SVV) is the percentage change in SV between a group of beats. SVV = (SVmax - SVmin x 100) / [(SVmax + SVmin)/2].
  • Systemic vascular resistance (SVR) is the pressure against which the heart pumps. SVR = MAP/CO. The unit is d.s.cm-5.
  • Systemic vascular resistance index (SVRI) SVRI = SVR x BSA d.s.cm-5m2.
  • Oxygen delivery (DO2) is calculated by the equation: DO2 = 1.34 x Hb x SpO2/100 x CO, where Hb = hemoglobin in grams of hemoglobin per litre of blood (g/l); SpO2 = the peripheral oxygen saturation as a percentage (%). The unit of DO2 is ml/min.
  • Oxygen delivery index (DO2I) is equal to DO2 divided by BSA. The unit of DO2I is ml/min/m2.
  • Inotropy index refers to (Potential energy + Kinetic energy) divided by body surface area. The unit of inotropy is W/m2.

This project will provide essential data on the potential for clinicians without access to echocardiography but with access to USCOM, to effectively and safely assess patients with cHF, and adHF. Confirming the value of USCOM will enable the earlier diagnosis of heart failure and cardiogenic shock, earlier appropriate management, will remove the guesswork and uncertainty as whether or not to administer diuretics, intravenous fluid, vasodilators, vasoconstrictors, inotropes, chronotropes or blockers. This will open the door for trials orientated to optimizing haemodynamics in the cold and acute critical care settings, thus permitting optimal use of life-saving therapies, and optimizing survival. Such early treatment options should reduce the need for admission to hospital and length of hospital stay.

Being tested
Ultrasonic cardiac output monitor, Echocardiography
Keywords
Heart Failure, Hemodynamics, Echocardiography, Diagnostic techniques and procedures, Ultrasonography, USCOM
Medical subject headings
Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasonic cardiac output monitorDevice

    Also called USCOM

    An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.

  • EchocardiographyDevice

    Also called Echo

    2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.

Study groups in NCT02289508
Study groupRoleWhat they receive
acute decompensated heart failurePatients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
Receives: Device: Ultrasonic cardiac output monitor; Device: Echocardiography
compensated heart failurecompensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
Receives: Device: Ultrasonic cardiac output monitor; Device: Echocardiography
non-heart failure patientsNon-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
Receives: Device: Ultrasonic cardiac output monitor; Device: Echocardiography
healthy controlsHealthy controls are subjects with not acute or chronic illness.
Receives: Device: Ultrasonic cardiac output monitor

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Difference in mean (SD) inotropy between New York Heart Association (NYHA) stages I, II, III and IV

    Inotropy = (Potential energy + kinetic energy) divided by BSA; measured at aortic and pulmonary window by USCOM; units W/m2

    Measured: On Day 1

Secondary outcomes (5)
  1. Difference in mean (SD) vti, FTc, SV, SVI, CO, CI, MD, SVR, SVRI, SVV, DO2, DO2I, Inotropy and ejection fraction

    Please see an explanation of these variables and units in the section on detailed description

    Measured: On Day 1

  2. Difference in mean (SD) vti, FTc, SV, SVI, CO, CI, MD, SVR, SVRI, SVV, DO2, DO2I, Inotropy and AHA stage

    Please see an explanation in of these variables and units in the section on detailed description

    Measured: On Day 1

  3. Agreement between CO and SV measured separately by USCOM and 2D-Echo

    Cardiac output (CO) is the volume of blood pumped by the heart in one minute (CO = SV x HR); units L/min.

    Measured: On Day 1

  4. Number of subjects with and without Major Adverse Cardiac Events (MACE).

    MACE are presented in total, and also as separate safety and intervention subgroups.

    Measured: 30-days, 6-months and 1-year

  5. Number of subjects with and without acute decompensated heart failure syndrome (adHFS)

    The presence or absence of adHFS is defined according to the Framingham criteria.

    Measured: On Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2014 (estimated)
  2. Study startNov 2014
  3. Primary completion6 Feb 2018
  4. Study completion6 Feb 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
242 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02289508
Sponsor's protocol ID
2014.464
Status last verified
Feb 2018
First submitted
6 Nov 2014
Last updated
7 Feb 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided: Data may be shared pending external requests.

Publications

  • McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000 May;83(5):596-602. doi: 10.1136/heart.83.5.596. No abstract available.

    PubMed 10768918
  • Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 2001 Sep-Oct;80(2-3):213-9. doi: 10.1016/s0167-5273(01)00497-1.

    PubMed 11578717
  • Sanderson JE, Tse TF. Heart failure: a global disease requiring a global response. Heart. 2003 Jun;89(6):585-6. doi: 10.1136/heart.89.6.585. No abstract available.

    PubMed 12748201
  • Hung YT, Cheung NT, Ip S, Fung H. Epidemiology of heart failure in Hong Kong, 1997. Hong Kong Med J. 2000 Jun;6(2):159-62.

    PubMed 10895138
  • Peacock WF. Acute Emergency Department management of heart failure. Heart Fail Rev. 2003 Oct;8(4):335-8. doi: 10.1023/a:1026187013370.

    PubMed 14574053
  • Peacock WF. Heart failure management in the emergency department observation unit. Prog Cardiovasc Dis. 2004 Mar-Apr;46(5):465-85. doi: 10.1016/j.pcad.2003.12.004.

    PubMed 15179633
  • Burkhardt J, Peacock WF, Emerman CL. Predictors of emergency department observation unit outcomes. Acad Emerg Med. 2005 Sep;12(9):869-74. doi: 10.1197/j.aem.2005.03.534.

    PubMed 16141022
  • Peacock WF. Using the emergency department clinical decision unit for acute decompensated heart failure. Cardiol Clin. 2005 Nov;23(4):569-88, viii. doi: 10.1016/j.ccl.2005.08.014.

    PubMed 16278126
  • Silver MA, Peacock WF 4th, Diercks DB. Optimizing treatment and outcomes in acute heart failure: beyond initial triage. Congest Heart Fail. 2006 May-Jun;12(3):137-45. doi: 10.1111/j.1527-5299.2006.05413.x.

    PubMed 16760699
  • Kosowsky JM, Gasaway MD, Hamilton CA, Storrow AB. Preliminary experience with an emergency department observation unit protocol for heart failure. Acad Emerg Med. 2000 Oct;7(10):1171.

    PubMed 11015282
  • Sanderson JE, Chan SK, Chan WW, Hung YT, Woo KS. The aetiology of heart failure in the Chinese population of Hong Kong--a prospective study of 730 consecutive patients. Int J Cardiol. 1995 Aug;51(1):29-35. doi: 10.1016/0167-5273(95)02398-g.

    PubMed 8522394
  • Diercks DB, Peacock WF, Kirk JD, Weber JE. ED patients with heart failure: identification of an observational unit-appropriate cohort. Am J Emerg Med. 2006 May;24(3):319-24. doi: 10.1016/j.ajem.2005.11.014.

    PubMed 16635705
  • Juan A, Salazar A, Alvarez A, Perez JR, Garcia L, Corbella X. Effectiveness and safety of an emergency department short-stay unit as an alternative to standard inpatient hospitalisation. Emerg Med J. 2006 Nov;23(11):833-7. doi: 10.1136/emj.2005.033647.

    PubMed 17057132
  • Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol. 2007 Jul 31;50(5):381-96. doi: 10.1016/j.jacc.2007.03.048. Epub 2007 Jul 13.

    PubMed 17662389
  • Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, Tajik AJ, Seward JB. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function--a study in normals and dilated cardiomyopathy. J Cardiol. 1995 Dec;26(6):357-66.

    PubMed 8558414

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Decompensated Heart Failure and Congestive Heart Failure Compensated, run by Chinese University of Hong Kong at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Feb 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Difference in mean (SD) inotropy between New York Heart Association (NYHA) stages I, II, III and IV (time frame: On Day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02289508, which also lists 24 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Feb 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in